PMID- 26151622
OWN - NLM
STAT- MEDLINE
DCOM- 20160624
LR  - 20221207
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 12
IP  - 4
DP  - 2015 Oct
TI  - 1‑O‑acetylbritannilactone combined with gemcitabine elicits growth inhibition and 
      apoptosis in A549 human non‑small cell lung cancer cells.
PG  - 5568-72
LID - 10.3892/mmr.2015.4042 [doi]
AB  - Non‑small‑cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases, 
      with a 5‑year survival rate of <15%. 1‑O‑acetylbritannilactone (ABL), a natural 
      chemical component obtained from inula britannica, a Chinese traditional 
      medicine, has been demonstrated to have anticancer activity. In the present 
      study, the antiproliferative and proapoptotic abilities of ABL alone or in 
      combination with gemcitabine in a human NSCLC cell line were investigated. A549 
      cells were treated in vitro with ABL, gemcitabine, and a combination of ABL and 
      gemcitabine for 72 h. The results demonstrated that ABL and gemcitabine inhibited 
      cell growth and induced apoptosis of A549 cells. These effects were more potent 
      following the combination of ABL and gemcitabine treatment than either agent 
      alone. Furthermore, the signal transduction analysis revealed nuclear factor 
      (NF)‑kappaB expression was significantly decreased by ABL and the combination 
      treatment. The inhibitor nuclear factor kappaBalpha (IkappaBalpha) and Bax levels were 
      upregulated whereas Bcl‑2 was substantially downregulated following treatment. 
      The present findings suggest that ABL combined with gemcitabine elicits potent 
      apoptosis of lung cancer cells and therefore, ABL has the potential to be 
      developed as a chemotherapeutic agent.
FAU - Wang, Feng
AU  - Wang F
AD  - Department of Thoracic Surgery, Shanghai Ninth People's Hospital, Shanghai 
      JiaoTong University School of Medicine, Shanghai 200011, P.R. China.
FAU - Li, Hong
AU  - Li H
AD  - Department of Emergency, Shanghai Chest Hospital, Shanghai JiaoTong University 
      School of Medicine, Shanghai 200011, P.R. China.
FAU - Qiao, Jian-Ou
AU  - Qiao JO
AD  - Department of Respiratory Medicine, Shanghai Ninth People's Hospital, Shanghai 
      JiaoTong University School of Medicine, Shanghai 200011, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150703
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antineoplastic Agents)
RN  - 0 (BAX protein, human)
RN  - 0 (BCL2 protein, human)
RN  - 0 (Drug Combinations)
RN  - 0 (I-kappa B Proteins)
RN  - 0 (Lactones)
RN  - 0 (NF-kappa B)
RN  - 0 (NFKBIA protein, human)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (acetylbritannilatone)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 139874-52-5 (NF-KappaB Inhibitor alpha)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Deoxycytidine/*analogs & derivatives/pharmacology
MH  - Drug Combinations
MH  - Drug Synergism
MH  - Epithelial Cells/*drug effects/metabolism/pathology
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - I-kappa B Proteins/agonists/genetics/metabolism
MH  - Lactones/*pharmacology
MH  - NF-KappaB Inhibitor alpha
MH  - NF-kappa B/antagonists & inhibitors/genetics/metabolism
MH  - Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors/genetics/metabolism
MH  - Respiratory Mucosa/drug effects/metabolism/pathology
MH  - Signal Transduction
MH  - bcl-2-Associated X Protein/agonists/genetics/metabolism
MH  - Gemcitabine
EDAT- 2015/07/08 06:00
MHDA- 2016/06/25 06:00
CRDT- 2015/07/08 06:00
PHST- 2013/11/09 00:00 [received]
PHST- 2014/06/17 00:00 [accepted]
PHST- 2015/07/08 06:00 [entrez]
PHST- 2015/07/08 06:00 [pubmed]
PHST- 2016/06/25 06:00 [medline]
AID - 10.3892/mmr.2015.4042 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Oct;12(4):5568-72. doi: 10.3892/mmr.2015.4042. Epub 2015 Jul 3.